The Osimertinib Drugs Market centers on osimertinib, a third‑generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) used primarily to treat non‑small cell lung cancer (NSCLC) with specific EGFR mutations. Osimertinib is designed to target both activating EGFR mutations and the T790M resistance mutation, while sparing wild‑type EGFR to reduce certain toxicities. It...